Published in FEBS Lett on July 23, 1999
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Optimizing dentin bond durability: control of collagen degradation by matrix metalloproteinases and cysteine cathepsins. Dent Mater (2012) 1.39
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res (2008) 1.20
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia (2008) 1.19
Cathepsin B as a cancer target. Expert Opin Ther Targets (2013) 1.19
Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia (2005) 1.11
Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J (2014) 0.92
Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer (2015) 0.89
Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. Biochem J (2002) 0.85
IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity. Neoplasia (2013) 0.85
Role of cathepsin B in regulating migration and invasion of fibroblast-like synoviocytes into inflamed tissue from patients with rheumatoid arthritis. Clin Exp Immunol (2014) 0.85
Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer. World J Gastroenterol (2005) 0.83
Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model. Mol Ther (2010) 0.82
Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft. Biochem J (2004) 0.81
Osteoarthritis in temporomandibular joint of Col2a1 mutant mice. Arch Oral Biol (2013) 0.81
Activity-Dependent Exocytosis of Lysosomes Regulates the Structural Plasticity of Dendritic Spines. Neuron (2016) 0.79
Cathepsin B expression and down-regulation by gene silencing and antisense DNA in human chondrocytes. Biochem J (2002) 0.79
Role of Chondrocytes in Cartilage Formation, Progression of Osteoarthritis and Cartilage Regeneration. J Dev Biol (2015) 0.78
Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res (2015) 0.78
How does heparin prevent the pH inactivation of cathepsin B? Allosteric mechanism elucidated by docking and molecular dynamics. BMC Genomics (2010) 0.78
Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer (2016) 0.77
Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions. Clin Exp Metastasis (2000) 0.76
Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo. Oncotarget (2017) 0.75
Gibberellins and Light Inhibition of Stem Growth in Peas. Plant Physiol (1964) 11.01
Effect of some (2-chloroethyl) trimethylammonium chloride analogs and other growth retardants on gibberellin biosynthesis in Fusarium moniliforme. Plant Physiol (1965) 6.08
Evidence for Substances in Higher Plants Interfering with Response of Dwarf Peas to Gibberellin. Plant Physiol (1963) 5.86
Fate of radioactive gibberellin a(1) in maturing and germinating seeds of peas and Japanese morning glory. Plant Physiol (1968) 5.73
Lettuce Seed Germination: Evidence for a Reversible Light-Induced Increase in Growth Potential and for Phytochrome Mediation of the Low Temperature Effect. Plant Physiol (1965) 5.73
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet (1992) 5.14
Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A (1992) 4.13
Extractable and Diffusible Gibberellins From Light- and Dark-grown Pea Seedlings. Plant Physiol (1968) 4.02
Kinetics of molecular chaperone action. Science (1994) 3.91
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature (1991) 2.60
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem (2001) 2.58
Physiological effects of gibberellic acid. 8. Growth retardants on barley endosperm. Plant Physiol (1965) 2.58
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Inhibition of cell division and cell elongation in higher plants by inhibitors of DNA synthesis. Dev Biol (1965) 2.38
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33
Contents and recovery of gibberellins in monoecious and gynoecious cucumber plants. Plant Physiol (1968) 2.20
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Management of Parkinson's disease a review of current and new therapies. Can J Neurol Sci (1999) 2.16
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry (1990) 2.06
The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res (1998) 1.94
DNA synthesis in the elongating nondividing cells of the lentil epicotyl and its promotion by gibberellin. Plant Physiol (1966) 1.94
Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (1998) 1.90
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Optical performance of multifocal intraocular lenses. J Cataract Refract Surg (1990) 1.74
Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest (1992) 1.74
Degradation of chromosomal DNA during apoptosis. Cell Death Differ (2003) 1.73
Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res (1998) 1.71
Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis (1989) 1.71
Food allergy as a risk factor for nutritional rickets. Pediatr Allergy Immunol (2004) 1.69
Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem (1996) 1.69
Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol (2001) 1.65
Comparison of endogenous gibberellins and of the fate of applied radioactive gibberellin a(1) in a normal and a dwarf strain of Japanese morning glory. Plant Physiol (1972) 1.57
The Products of CO(2) Fixation in Leaves of Long- and Short-Day Treated Kalanchoë blossfeldiana. Plant Physiol (1957) 1.56
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem (1988) 1.54
Induction of Flowering in Long Day Plants by Applied Indoleacetic Acid. Plant Physiol (1956) 1.53
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res (2000) 1.53
Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther (1992) 1.51
Detection of 12 germ-line mutations in the adenomatous polyposis coli gene by polymerase chain reaction. Gastroenterology (1993) 1.49
Effect of Gibberellin on Cell Division in Hyoscyamus. Science (1957) 1.48
Kinetics of folding of leucine zipper domains. Biochemistry (1995) 1.47
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res (1992) 1.47
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 1.43
Lettuce seed germination: effects of high temperature and of repeated far-red treatment in relation to phytochrome. Photochem Photobiol (1969) 1.42
Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest (1989) 1.42
Purification of an endogenous activator of procollagenase from rabbit synovial fibroblast culture medium. J Biol Chem (1983) 1.42
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett (1988) 1.39
Analysis of edge glare phenomena in intraocular lens edge designs. J Cataract Refract Surg (1999) 1.38
Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol (1999) 1.38
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol (1997) 1.36
Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem (2000) 1.35
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem (2000) 1.32
Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem (1994) 1.32
The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J (1988) 1.30
An improved assay for proteases and polysaccharidases employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem (1980) 1.29
Very rapid, ionic strength-dependent association and folding of a heterodimeric leucine zipper. Biochemistry (1997) 1.28
Relationship of aging to Parkinson's disease. Adv Neurol (1987) 1.28
Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem (1991) 1.28
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys (1988) 1.24
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int (1997) 1.23
Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb (1994) 1.23
A precursor form of latent collagenase produced in a cell-free system with mRNA from rabbit synovial cells. J Biol Chem (1981) 1.22
A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem (1999) 1.22
The specific velocity plot. A graphical method for determining inhibition parameters for both linear and hyperbolic enzyme inhibitors. Eur J Biochem (1981) 1.21
Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. Chem Biol (2000) 1.21
Biosynthesis and secretion of procollagenase by rabbit synovial fibroblasts. Inhibition of procollagenase secretion by monensin and evidence for glycosylation of procollagenase. Biochem J (1983) 1.21
Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem (1995) 1.20
Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3. Biochem J (1989) 1.20
Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res (1999) 1.20
Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum (1998) 1.19
Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet (1998) 1.19
Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates. Biochemistry (2001) 1.19
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet (1997) 1.18
The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem (2001) 1.17
The power stroke of the DnaK/DnaJ/GrpE molecular chaperone system. J Mol Biol (1997) 1.17
Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem (1998) 1.17
Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett (1996) 1.16
Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res (1994) 1.16
Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer (1995) 1.14
Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J (1995) 1.14
The slow, tight-binding inhibition of cathepsin B by leupeptin. A hysteretic effect. Eur J Biochem (1982) 1.14
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1991) 1.13
The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem (1997) 1.13
Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta (1982) 1.13
The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem (1998) 1.12
Schistosoma mansoni-related morbidity on Ukerewe Island, Tanzania: clinical, ultrasonographical and biochemical parameters. Trop Med Int Health (1997) 1.12